Another clinical trial performed in 2011 by Rastelli et al. showed that aromatase inhibitor-induced musculoskeletal symptoms in breast cancer can be reduced using 4 months of treatment with vitamin D2. Here, CYP19A1 is linked to breast carcinoma.